Garlock Estimation: A Science Case

Garlock is often remembered for what the bankruptcy court found about undisclosed exposures to other asbestos products. Those findings told the court why Garlock’s settlement history could not be trusted as a proxy for the claims’ value. They did not tell it what the claims were worth.

To estimate the liability, the court needed a different measure. It used the scientific evidence: dose, fiber type, alternative exposures, and causation.

The court found that in the tort system Garlock had settled with claimants who did not disclose exposure to friable amphibole products made by others, and who then filed claims against the trusts those manufacturers had established, asserting exposure to exactly those products. It found the practice widespread, and states have since enacted statutes requiring claimants to disclose their trust filings.

A settlement is a price, not a finding. Garlock’s risk at trial was that a jury would hear about its gaskets and hear little or nothing of friable products made by others. The court said evidence of those other exposures “was essential to” Garlock’s defense and to its negotiating position.1 Its absence drove up the settlements, and so did the cost of defending a trial.2 Those settlements are not a measure of Garlock’s legal liability.

So the court set the settlement history aside.

The claims resolution history may be an appropriate measure only if it reliably reflects the debtor’s liability, and here it does not.3

The measure it used instead rested on the evidence of dose, potency, and exposure to the products of others. Work with Garlock’s gaskets and packing, the court held, produced “relatively low exposure of a relatively lower potency asbestos to a limited population,” and the people doing that work were “necessarily exposed to far greater quantities of higher potency asbestos from the products of others.”4 The court declined to go further than it had to, saying expressly that it was not deciding, one way or the other, whether low-dose chrysotile exposure from Garlock gaskets could cause mesothelioma.

The same reasoning had produced a published holding three years earlier. In Moeller v. Garlock Sealing Technologies, LLC, the Sixth Circuit compared the plaintiff’s gasket exposure to “a bucket of water” against “the ocean’s volume” and held the evidence insufficient to make the gaskets a substantial cause.5 The comparison is a statement about relative magnitude. It works only because one quantity is small.

The bankruptcy court quoted that comparison, holding that the best evidence of Garlock’s aggregate responsibility was “the projection of its legal liability that takes into consideration causation, limited exposure and the contribution of exposures to other products.”6 On that projection, it determined that $125 million was sufficient to satisfy Garlock’s liability for the present and future mesothelioma claims against it, compared with the claimants’ representatives’ estimate of more than $1 billion. That figure is not a measure of harm that Garlock’s products were found to have caused.

The nondisclosure findings explain why the settlement history was set aside. What replaced it rested on the scientific evidence.

Notes

  1. In re Garlock Sealing Technologies, LLC, 504 B.R. 71, 83 (Bankr. W.D.N.C. 2014). ↩
  2. Id. at 73. ↩
  3. Id. at 94. ↩
  4. Id. at 82. ↩
  5. Moeller v. Garlock Sealing Technologies, LLC, 660 F.3d 950, 954–55 (6th Cir. 2011). ↩
  6. In re Garlock, 504 B.R. at 73. ↩